Developer docs
API playgroundTry for free, no card

Search company profiles

Inventiva Pharma

Full company profile

uuid0002a8x

Namestring
Inventiva Pharma
Legal namestring
Inventiva S.A.
Company typeenum
Public
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDaix, France
HQ citystring
Daix
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, MASH drug development, oral liver therapeutics, pan-PPAR agonist, metabolic disease treatments
Industry3 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
MASH Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and milestone revenues
TypeLicensing Royalties
Description

Inventiva generates revenue through licensing agreements with partners, including milestone payments from CTTQ/Sino Biopharm for China development and Hepalys Pharma for Japan/South Korea. The company reported revenues of €4.5 million in 2025 (down from €9.2 million in 2024), primarily from licensing agreement milestones.

globenewswire.com
2Future product sales (pre-commercial)
TypeOne Time License
Description

Inventiva is pre-commercial, with lanifibranor in Phase 3 development. Upon regulatory approval, the company plans to commercialize lanifibranor for MASH treatment, targeting a projected market of $24 billion by 2035 according to analyst estimates.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, an oral pan-PPAR agonist therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The drug simultaneously targets the three core drivers of MASH progression: metabolic dysfunction, inflammation, and fibrosis in a single oral investigational therapy. Lanifibranor is currently completing a global pivotal Phase 3 NATiV3 clinical trial following positive Phase 2b NATIVE results, with FDA Breakthrough Therapy and Fast Track Designations supporting expedited regulatory review.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2b NATIVE trial demonstrated improvements in liver fibrosis and MASH resolution
+2 more records
Product overview1 text field

Inventiva Pharma is a clinical-stage biopharmaceutical company developing a novel oral treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's primary product candidate is lanifibranor, an oral pan-PPAR agonist that simultaneously targets the core biological drivers of MASH: metabolic dysfunction, inflammation, and fibrosis. The company is advancing lanifibranor through a global Phase 3 clinical trial (NATiV3) following positive Phase 2b results. Inventiva has received Breakthrough Therapy and Fast Track designations from the FDA for lanifibranor.

Product and service1 record
1Lanifibranor
CategoryMASH Therapeutics
Description

Oral pan-PPAR (peroxisome proliferator-activated receptor) agonist investigational therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH), targeting metabolic dysfunction, inflammation, and fibrosis simultaneously in a single oral therapy. Currently in Phase 3 NATiV3 clinical development following positive Phase 2b NATIVE results.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1CTTQ (Sino Biopharm subsidiary)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-07
Description

Inventiva received $10 million milestone payment from CTTQ following successful financing and clinical trial progress. CTTQ holds license for lanifibranor development and commercialization in China. Sino Biopharm received NMPA IND approval for clinical development in China.

globenewswire.com
2Hepalys Pharma, Inc.
Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2023-09-20
Description

Inventiva and Hepalys Pharma signed exclusive license agreement to develop and commercialize lanifibranor in Japan and South Korea. First participant included in Phase 1 study in Japan.

globenewswire.com
3Echosens
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-08
Description

Inventiva and Echosens launched joint initiative to raise awareness about NASH and facilitate access to screening for at-risk patients.

globenewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-31
Description

Inventiva partnered with AbbVie for development of cedirogant (ABBV-154), an RORγ agonist for autoimmune diseases including psoriasis. Inventiva received $4 million milestone payment following initiation of Phase IIb study.

5Sino Biopharm
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-21
Description

Inventiva and Sino Biopharm signed licensing and collaboration agreement to develop and commercialize lanifibranor in China. Includes potential milestone payments and royalties based on development and sales progress.

globenewswire.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in diabetes/obesity with semaglutide (Wegovy/Ozempic) advancing through Phase 3 in MASH; broad metabolic disease incumbent that competes for the same MASH patient population.

TypeBroad incumbent
Description

Large pharmaceutical company whose tirzepatide (Mounjaro/Zepbound) and retatrutide are demonstrating strong MASH efficacy in Phase 3; broad metabolic disease incumbent that pressures the addressable market for lanifibranor.

TypeBroad incumbent
Description

Large pharmaceutical company with active MASH pipeline programs and significant commercial infrastructure; relevant incumbent peer and potential acquirer of differentiated late-stage MASH assets like lanifibranor.

TypeDirect peer
Description

Clinical-stage biotech with MASH programs (formerly aldafermin and related metabolic liver assets); comparable small-cap hepatology R&D profile to Inventiva.

TypeDirect peer
Description

Developing TERN-501 (oral THR-β agonist) for MASH; small-cap clinical-stage peer pursuing differentiated oral MASH mechanism similar to lanifibranor's positioning.

TypeDirect peer
Description

Clinical-stage biotech developing VK2809 (oral thyroid receptor beta agonist) for MASH and VK2735 for obesity; pursues overlapping metabolic liver disease indications with lanifibranor.

TypeDirect peer
Description

Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH; competes with lanifibranor in the advanced fibrosis MASH segment with Phase 3 HARMONY data.

TypeDirect peer
Description

Developing pegozafermin, a long-acting FGF21 analog for MASH with positive Phase 2b/3 data; directly comparable to lanifibranor as a late-stage MASH-focused biotech.

TypeDirect peer
Description

Developer of resmetirom (Rezdiffra), the first FDA-approved oral therapy for MASH with moderate-to-advanced fibrosis; direct late-stage competitor to lanifibranor in the same MASH indication.

TypeDirect peer
Description

Clinical-stage developer of aramchol for MASH; small-cap MASH-focused peer with similar profile to Inventiva as a single-asset hepatology biotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inventiva Pharma

MASH Therapeuticsinventivapharma.com

Inventiva Pharma firmographics

Firmographics
Name
Inventiva Pharma
Legal name
Inventiva S.A.
Website
https://inventivapharma.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Inventiva Pharma industry classification

Industry
Product category
MASH Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • MASH drug development
  • Oral liver therapeutics
  • Pan-PPAR agonist
  • Metabolic disease treatments

Where Inventiva Pharma is headquartered

Location

Headquarters

HQ city
Daix
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Inventiva Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Licensing and milestone revenues: Inventiva generates revenue through licensing agreements with partners, including milestone payments from CTTQ/Sino Biopharm for China development and Hepalys Pharma for Japan/South Korea. The company reported revenues of €4.5 million in 2025 (down from €9.2 million in 2024), primarily from licensing agreement milestones.
  2. Future product sales (pre-commercial): Inventiva is pre-commercial, with lanifibranor in Phase 3 development. Upon regulatory approval, the company plans to commercialize lanifibranor for MASH treatment, targeting a projected market of $24 billion by 2035 according to analyst estimates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Inventiva Pharma product offering

Product offering

Core offering

Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, an oral pan-PPAR agonist therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The drug simultaneously targets the three core drivers of MASH progression: metabolic dysfunction, inflammation, and fibrosis in a single oral investigational therapy. Lanifibranor is currently completing a global pivotal Phase 3 NATiV3 clinical trial following positive Phase 2b NATIVE results, with FDA Breakthrough Therapy and Fast Track Designations supporting expedited regulatory review.

Product overview

Inventiva Pharma is a clinical-stage biopharmaceutical company developing a novel oral treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's primary product candidate is lanifibranor, an oral pan-PPAR agonist that simultaneously targets the core biological drivers of MASH: metabolic dysfunction, inflammation, and fibrosis. The company is advancing lanifibranor through a global Phase 3 clinical trial (NATiV3) following positive Phase 2b results. Inventiva has received Breakthrough Therapy and Fast Track designations from the FDA for lanifibranor.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lanifibranor Oral pan-PPAR (peroxisome proliferator-activated receptor) agonist investigational therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH), targeting metabolic dysfunction, inflammation, and fibrosis simultaneously in a single oral therapy. Currently in Phase 3 NATiV3 clinical development following positive Phase 2b NATIVE results.

Quantifiable outcome

  • Phase 2b NATIVE trial demonstrated improvements in liver fibrosis and MASH resolution
  • +2 more outcomes

Companies that use Inventiva Pharma

Customer profile

Segments1 record

Ideal customer profiles3 records

Inventiva Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Inventiva Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, regional and minor.

  • CTTQ (Sino Biopharm subsidiary)coreStrategic or Co-development Partner · 7 July 2025Inventiva received $10 million milestone payment from CTTQ following successful financing and clinical trial progress. CTTQ holds license for lanifibranor development and commercialization in China. Sino Biopharm received NMPA IND approval for clinical development in China.
  • Hepalys Pharma, Inc.regionalStrategic or Co-development Partner · 20 September 2023Inventiva and Hepalys Pharma signed exclusive license agreement to develop and commercialize lanifibranor in Japan and South Korea. First participant included in Phase 1 study in Japan.
  • EchosensminorStrategic or Co-development Partner · 8 June 2023Inventiva and Echosens launched joint initiative to raise awareness about NASH and facilitate access to screening for at-risk patients.
  • AbbVieminorStrategic or Co-development Partner · 31 October 2022Inventiva partnered with AbbVie for development of cedirogant (ABBV-154), an RORγ agonist for autoimmune diseases including psoriasis. Inventiva received $4 million milestone payment following initiation of Phase IIb study.
  • Sino BiopharmcoreStrategic or Co-development Partner · 21 September 2022Inventiva and Sino Biopharm signed licensing and collaboration agreement to develop and commercialize lanifibranor in China. Includes potential milestone payments and royalties based on development and sales progress.

Scale indicators11 records

Recent moves5 records

Expansion highlights4 records

Inventiva Pharma competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global leader in diabetes/obesity with semaglutide (Wegovy/Ozempic) advancing through Phase 3 in MASH; broad metabolic disease incumbent that competes for the same MASH patient population.
  • Eli Lilly: Large pharmaceutical company whose tirzepatide (Mounjaro/Zepbound) and retatrutide are demonstrating strong MASH efficacy in Phase 3; broad metabolic disease incumbent that pressures the addressable market for lanifibranor.
  • Pfizer: Large pharmaceutical company with active MASH pipeline programs and significant commercial infrastructure; relevant incumbent peer and potential acquirer of differentiated late-stage MASH assets like lanifibranor.

Direct peers

  • NGM Biopharmaceuticals: Clinical-stage biotech with MASH programs (formerly aldafermin and related metabolic liver assets); comparable small-cap hepatology R&D profile to Inventiva.
  • Terns Pharmaceuticals: Developing TERN-501 (oral THR-β agonist) for MASH; small-cap clinical-stage peer pursuing differentiated oral MASH mechanism similar to lanifibranor's positioning.
  • Viking Therapeutics: Clinical-stage biotech developing VK2809 (oral thyroid receptor beta agonist) for MASH and VK2735 for obesity; pursues overlapping metabolic liver disease indications with lanifibranor.
  • Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH; competes with lanifibranor in the advanced fibrosis MASH segment with Phase 3 HARMONY data.
  • 89bio: Developing pegozafermin, a long-acting FGF21 analog for MASH with positive Phase 2b/3 data; directly comparable to lanifibranor as a late-stage MASH-focused biotech.
  • Madrigal Pharmaceuticals: Developer of resmetirom (Rezdiffra), the first FDA-approved oral therapy for MASH with moderate-to-advanced fibrosis; direct late-stage competitor to lanifibranor in the same MASH indication.
  • Galmed Pharmaceuticals: Clinical-stage developer of aramchol for MASH; small-cap MASH-focused peer with similar profile to Inventiva as a single-asset hepatology biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Inventiva Pharma social profiles

Digital presence

Inventiva Pharma compliance and trust

Trust signal

Compliance1 record

Inventiva Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inventiva Pharma leadership team

Management profile

Number of profiles

Profiles10 records

Inventiva Pharma funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inventiva Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inventiva Pharma

What does Inventiva Pharma do?

Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, an oral pan-PPAR agonist therapeutic candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The drug simultaneously targets the three core drivers of MASH progression: metabolic dysfunction, inflammation, and fibrosis in a single oral investigational therapy. Lanifibranor is currently completing a global pivotal Phase 3 NATiV3 clinical trial following positive Phase 2b NATIVE results, with FDA Breakthrough Therapy and Fast Track Designations supporting expedited regulatory review.

Is Inventiva Pharma a public or private company?

Inventiva Pharma is a public company. It is classified as public and is currently operating.

When was Inventiva Pharma founded?

Inventiva Pharma was founded in 2012. It employs 101 to 250 people.

Where is Inventiva Pharma based?

Inventiva Pharma is headquartered in Daix, France, in the Europe region.

How does Inventiva Pharma make money?

Two revenue lines are on record. Licensing and milestone revenues are the primary driver. The others are future product sales (pre-commercial).

Who are Inventiva Pharma's main competitors?

Broad incumbents on record are Novo Nordisk, Eli Lilly and Pfizer. Direct peers are NGM Biopharmaceuticals, Terns Pharmaceuticals, Viking Therapeutics, Akero Therapeutics, 89bio, Madrigal Pharmaceuticals and Galmed Pharmaceuticals.

Does Inventiva Pharma have an API?

No public API is recorded for Inventiva Pharma.

What industry is Inventiva Pharma in?

Inventiva Pharma's product category is MASH Therapeutics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comInventiva at guggenheim healthcare conference: lanifibranor nears key readoutInventiva announced its Phase III readout for lanifibranor in MASH is expected within nine weeks of the quarter. Phase IIb data showed an 18% effect on fibrosis regression and 24% on the primary endpoint, with edema rates of 7-8% versus 20-25% for pioglitazone. The company plans to file a New Drug Application in the first half of 2027 if results are positive.MarketBeatInventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.86Analysts rate Inventiva S.A. ADR with an average price target of $15.86, with seven buy ratings and one sell. The stock opened at $3.71, and the company reported a quarterly loss of $0.14 per share. Institutional investors hold 19.06% of the company.Markets DailyInventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Report for SeptemberInventiva's short interest rose 71.9% to 8,346,026 shares as of September 30, with 5.9% of shares short sold. Analysts have an average "Buy" rating and a consensus target price of $15.86, while the stock traded down 5.5% to $2.94. The company reported a loss of $0.14 per share for the quarter.MarketBeatInventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Rises 71.9%Short interest in Inventiva's ADR rose 71.9% to 8.35 million shares as of September 30, while shares traded up 7.8% to $3.10. The company reported a quarterly loss of $0.14 per share on $0.75 million revenue, and analysts have a consensus Buy rating with a $15.86 target.Les EchosLa biotech dijonnaise Inventiva reste dans une situation financière très tendueInventiva, a Dijon-based biotech, reported no revenue in the first half of 2026, with only €1.2M from the R&D tax credit. Its net loss narrowed to €69.4M from €176M in the same period of 2025, as it develops an oral treatment for non-alcoholic fatty liver disease.MarketBeat3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts AheadThree small-cap biotech stocks—Inventiva, Larimar Therapeutics, and Ascentage Pharma Group—are highlighted for triple-digit upside potential. Inventiva's Phase 3 MASH trial results are expected in Q4 2026, Larimar submitted its first FDA module for nomlabofusp, and Ascentage reported $44.5 million in H1 2026 revenue. Analysts assign Buy ratings with price targets implying over 200% upside for Ascentage.MarketBeat3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts AheadThree small-cap biotech stocks—Inventiva, Larimar Therapeutics, and Ascentage Pharma Group—are highlighted for triple-digit upside potential. Inventiva's Phase 3 MASH trial results are expected in Q4 2026, Larimar submitted its first FDA module, and Ascentage reported $44.5 million in H1 2026 revenue. Analysts assign Buy ratings with price targets implying over 200% upside.Markets DailyInventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Now Rated “Buy” by Sell-Side AnalystsAnalysts rate Inventiva S.A. ADR a consensus 'Buy' with an average 12-month target price of $15.86. The stock opened at $3.48, and institutional investors hold 19.06% of shares. The company reported a loss of $0.14 per share for the quarter.YahooInventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?Inventiva's stock hinges on its Phase III readout for liver drug lanifibranor in Q4 2026, which could de-risk its oral pipeline. The company lost €69.5 million in H1 2026, with cash extending only to Q2 2027. Management sees the MASH market at $15 billion by 2035.Insider Trading & Hedge Fund DataInventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?Inventiva's stock valuation hinges on its Phase III readout for liver drug lanifibranor, due in Q4 2026. The company lost €69.5 million in H1 2026, with cash running out by Q2 2027, and the market is estimated at $15 billion by 2035. A positive result could de-risk the pipeline, but a negative one would force further dilution.